Key facts
as of Sep 2026- It has raised $336.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($175.0M) in Sep 2024.
- Notable investors include RA Capital Management, T. Rowe Price Group, Bristol-Myers Squibb, RTW Investments, Avidity Partners — 23 tracked in total.
- 1 institutional filer reports fund marks on Aktis Oncology across 2 filings.
- Aktis Oncology has filed 1 Form D with the SEC, most recently Oct 2024 ($175.0M sold to 39 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$21per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Aktis Oncology
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Aktis Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 2 fair-value marks on Aktis Oncology between Feb 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsSep 2024Early Stage VC (Series B)$175.0M▮
About Aktis Oncology
Developer of a targeted radiopharmaceutical designed to treat a broad range of solid tumour cancers. The company's radiopharmaceuticals generate cell-targeting agents with ideal properties for alpha radiotherapy, which are designed for high tumour penetration and long residence time, enabling clinicians to maximise elimination while minimising side effects of treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 46
- Website
- aktisoncology.com/
- Ownership
- Privately Held (backing)